Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients


This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) presented interim results of the Phase 3 randomized SEQUOIA study which evaluated the efficacy and safety of zanubrutinib versus BR in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients without the high-risk mutation,17p deletion
Pushing Therapeutic Boundaries in CLLJoint Live Web Broadcast with CLL Society and PeerView Institute Recorded on June 14, 2021 Continuous or fixed-duration therapy with targeted agents, including BTK and BCL-2 inhibitors, is the new standard for management of chronic lymphocytic leukemia (CLL). New clinical questions that are pushing the
Making Modern Treatment Choices in CLLOncology Nurse Insights on the Patient Journey and the New Era of Care Recorded on April 22, 2021 CLL Society and PeerView Institute jointly provided a web broadcast in association with the 47th Annual ONS Congress. This NCPD/ILNA-certified program used PeerView’s “Nursing Clinical Consults”